Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Files An 8-K Regulation FD Disclosure
On November 21, 2019, management of Aclaris Therapeutics, Inc. (the “Company”) will present a company overview at SVB Leerink’s 13th Annual POLARxPRESS Bus Tour in New York, New York. The presentation will include a slide presentation. A copy of this slide presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
In accordance with General Instruction B.2. of Form 8-K, the information in this Item 7.01 and Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.